Who Owns Alkermes Company?

Alkermes Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Alkermes?

Uncover the forces driving innovation and value at Alkermes, a biopharmaceutical leader. Understanding the Alkermes SWOT Analysis is crucial for investors. This exploration dives deep into the ownership structure, revealing the key players shaping its future in the dynamic healthcare landscape.

From its inception to its current status as a publicly traded entity, Alkermes' ownership has undergone significant transformations. This analysis of Alkermes ownership will examine the influence of major institutional investors and the impact of its executives on the company's strategic direction. We'll explore the evolution of Alkermes shareholders and how their decisions affect the company's stock.

The story of Alkermes begins in 1987 with its founder, Michael Wall. He played a crucial role as the Chairman of the Board from the very beginning. While the specifics of the initial ownership structure aren't fully public, Wall's long-term leadership suggests significant early influence and ownership in the company.

Early biotechnology startups often had agreements to manage the interests of founders and early investors. These agreements could include vesting schedules or buy-sell clauses. These were designed to ensure that the founding team and early investors were aligned.

Alkermes' early focus on drug delivery technologies was key to its development. In 1999, Alkermes acquired Advanced Inhalation Research (AIR), which was a major step. This acquisition led to the development of the ARCUS technology.

Early Ownership

Michael Wall founded Alkermes in 1987 and served as Chairman of the Board.

Key Technology

The acquisition of Advanced Inhalation Research (AIR) in 1999 was pivotal for the development of ARCUS technology.

Spin-off and Value

Alkermes spun off ARCUS technology to Civitas Therapeutics in 2010, retaining a 6% stake. This demonstrates how early investments shaped the company's direction.

Financial Impact

Alkermes received $29 million from Civitas's acquisition in 2014 and an additional $30 million for manufacturing equipment.

Strategic Direction

The early technological investments and founding vision continued to yield value and shaped the company's evolving ownership and strategic direction.

Company Evolution

Alkermes' evolution from its founding to its current structure reflects its strategic decisions and technological advancements. This is a key part of understanding Alkermes' brief history.

Understanding the early ownership of Alkermes, including the roles of Michael Wall and the company's strategic moves, provides a crucial insight into the company's development. While specific details on early shareholders are not always available, the company's focus on drug delivery and technology, such as the ARCUS technology, has been central to its growth. The financial outcomes from these early investments, like the Civitas Therapeutics deal, demonstrate the long-term value of these strategic decisions. To learn more about the current state of the company, including its current Alkermes shareholders and Alkermes stock, it's important to review the most recent financial filings and ownership reports.

Alkermes SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Alkermes underwent a significant transformation in September 2011. This change occurred with the merger of Alkermes, Inc. and Elan Drug Technologies (EDT), a division of Elan Corporation, plc. This strategic move established Alkermes plc as an Irish-incorporated entity. Elan received $500 million in cash and 31.9 million ordinary shares of Alkermes plc, which represented roughly 25% of the newly formed company. Holders of Alkermes, Inc. stock received one ordinary share of Alkermes plc for each share they owned. Today, Alkermes plc is listed on the Nasdaq stock exchange under the ticker symbol 'ALKS'.

As of May 2025, the landscape of Alkermes ownership is heavily influenced by institutional investors. These investors collectively hold a substantial portion of the company's shares. There are 804 institutional owners and shareholders, reporting a total of 213,250,925 shares. This translates to an institutional ownership of 104.67% as of May 2025. Mutual funds increased their holdings from 79.83% to 80.55% during the same period. This demonstrates confidence from major investment firms, influencing company strategy through their significant voting power. If you're interested in understanding more about the company's financial aspects, you can explore the Revenue Streams & Business Model of Alkermes.

Key Takeaways on Alkermes Ownership

The ownership of Alkermes is largely dominated by institutional investors, indicating strong market confidence. The merger in 2011 was a pivotal moment, reshaping the company's structure. Understanding the major Alkermes shareholders is crucial for anyone interested in the company.

• Institutional investors hold a significant majority of shares.
• The merger with Elan Drug Technologies was a key event.
• BlackRock, Vanguard, and T. Rowe Price are among the major shareholders.
• Insider holdings remained unchanged at 1.42% as of May 2025.

Alkermes PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of Alkermes plc oversees the company's strategic direction and governance, representing the interests of its shareholders. While specific details of the board members for 2025 are not fully available in the provided search results, the company's definitive proxy statements (DEF 14A) filed with the SEC annually would contain this information. The company's Annual General Meeting of Shareholders was scheduled for May 21, 2025.

The company's commitment to shareholder engagement is evident through the active solicitation and response to shareholder feedback on matters such as corporate governance, executive compensation, and business strategy. The Lead Independent Director and other board members actively participate in these engagements. There were no indications of recent proxy battles or activist investor campaigns that significantly disrupted decision-making, according to the information available.

Alkermes operates under a one-share-one-vote structure. Shareholders voted on proposals, including the renewal of the Board's authority to disapply statutory pre-emption rights and issue new shares for cash, up to a maximum of 20% of its issued share capital. For more details on the company, including its target market, you can read the article Alkermes Target Market.

Key Takeaways on Alkermes Ownership

Understanding Alkermes ownership structure is crucial for investors and stakeholders. Alkermes shareholders have voting rights based on a one-share-one-vote system. The company's board plays a key role in governance and strategic oversight.

• The Board of Directors is responsible for the company's strategic direction.
• Shareholders vote on important matters at the Annual General Meeting.
• Alkermes actively engages with its shareholders.
• The DEF 14A filings provide detailed information about the board.

Alkermes Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Alkermes's strategic direction has seen significant shifts, impacting its ownership structure. A key move was the company's transition into a pure-play neuroscience entity. This involved the sale of its manufacturing business in Ireland to Novo Nordisk for $92.5 million, finalized in mid-2024. Additionally, the spin-off of its oncology business into Mural Oncology in November 2023 further streamlined its focus.

In February 2024, Alkermes announced a share repurchase program, which authorized the buyback of up to $400 million of its ordinary shares. By March 31, 2025, the company had repurchased 7,894,417 shares for $200.27 million under this plan. In 2024, Alkermes repurchased approximately 8 million shares for $200 million and retired approximately $290 million of debt, ending the year debt-free with approximately $825 million in cash and investments. These actions reflect a commitment to returning value to shareholders and managing its financial health.

The company anticipates total revenues for 2025 to be in the range of $1.34 billion to $1.43 billion, with proprietary product net sales between $1.09 billion and $1.15 billion. The increasing institutional ownership indicates growing investor confidence in Alkermes's strategic direction and its focus on the neuroscience market. These financial moves and ownership trends highlight Alkermes's proactive management of its financial structure and its commitment to maximizing shareholder value.

Alkermes Ownership Trends

Alkermes has focused on neuroscience, selling its manufacturing business and spinning off its oncology division. Share repurchase programs and debt reduction show a focus on shareholder value.

Share Repurchase Program

The company authorized a share repurchase program of up to $400 million. By March 31, 2025, they had repurchased 7,894,417 shares for $200.27 million.

Financial Performance

Alkermes anticipates 2025 revenues between $1.34 billion and $1.43 billion. Proprietary product net sales are expected between $1.09 billion and $1.15 billion.

Institutional Ownership

As of May 2025, 804 institutional owners held a total of 213,250,925 shares of Alkermes stock. This indicates strong investor confidence.

Alkermes Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs